Fulgent Genetics has acquired StrataDx - Strata Pathology Services Inc. for an undisclosed amount. StrataDx, operating for nearly three decades, is a prominent anatomic pathology laboratory known for providing diagnostic services to physicians, patients, and hospitals. The company's board-certified pathologists, including Drs. Lisa Cohen and Terence Harrist, specialize in delivering timely diagnoses for cancer and other diseases. StrataDx offers a comprehensive test menu across various clinical specialties, utilizing surgical pathology, cytology, immunofluorescence, and molecular diagnostic techniques.
This acquisition marks a strategic expansion for Fulgent Genetics, a company recognized for its advanced genetic testing and diagnostic solutions. The integration of StrataDx's established anatomic pathology capabilities is expected to significantly broaden Fulgent Genetics' service offerings. By combining StrataDx's deep expertise in traditional pathology with Fulgent's innovative genetic testing platforms, the combined entity aims to provide a more comprehensive suite of diagnostic tools.
The synergy between the two companies is anticipated to enhance diagnostic precision and patient care. StrataDx's robust infrastructure and specialized services in areas like surgical pathology and molecular diagnostics will complement Fulgent Genetics' existing genetic testing portfolio. This integration is designed to create a more holistic diagnostic pathway, allowing for a seamless transition from initial pathology findings to advanced genetic insights, ultimately benefiting healthcare providers and patients seeking integrated diagnostic solutions.
Looking ahead, the acquisition positions Fulgent Genetics to offer an expanded range of diagnostic services, from foundational anatomic pathology to cutting-edge genetic analysis. The combined entity is expected to leverage these integrated capabilities to drive innovation in diagnostic medicine and strengthen its market presence in the evolving healthcare landscape.